[go: up one dir, main page]

EP1423144A4 - METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE - Google Patents

METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE

Info

Publication number
EP1423144A4
EP1423144A4 EP02753530A EP02753530A EP1423144A4 EP 1423144 A4 EP1423144 A4 EP 1423144A4 EP 02753530 A EP02753530 A EP 02753530A EP 02753530 A EP02753530 A EP 02753530A EP 1423144 A4 EP1423144 A4 EP 1423144A4
Authority
EP
European Patent Office
Prior art keywords
cd40r
interrupting
compounds
treatment
signal transmission
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02753530A
Other languages
German (de)
French (fr)
Other versions
EP1423144A2 (en
Inventor
Jun Tan
Terrence C Town
Michael Mullan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roskamp Research LLC
Original Assignee
University of South Florida
University of South Florida St Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St Petersburg filed Critical University of South Florida
Priority claimed from PCT/US2002/027035 external-priority patent/WO2003014328A2/en
Publication of EP1423144A2 publication Critical patent/EP1423144A2/en
Publication of EP1423144A4 publication Critical patent/EP1423144A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4709Amyloid plaque core protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/525Tumor necrosis factor [TNF]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02753530A 2001-08-10 2002-08-12 METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE Withdrawn EP1423144A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31111501P 2001-08-10 2001-08-10
US311115P 2001-08-10
PCT/US2002/027035 WO2003014328A2 (en) 1999-06-01 2002-08-12 Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
EP1423144A2 EP1423144A2 (en) 2004-06-02
EP1423144A4 true EP1423144A4 (en) 2006-08-02

Family

ID=32298094

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02753530A Withdrawn EP1423144A4 (en) 2001-08-10 2002-08-12 METHOD AND COMPOUNDS FOR INTERRUPTING THE CD40R / CD40L SIGNAL TRANSMISSION IN THE TREATMENT OF ALZHEIMER DISEASE

Country Status (3)

Country Link
EP (1) EP1423144A4 (en)
AU (1) AU2002313811A1 (en)
CA (1) CA2467919A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023590A2 (en) * 1998-10-20 2000-04-27 Georgetown University Medical Center INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
WO2001096397A2 (en) * 2000-06-09 2001-12-20 Biogen, Inc. Cd154 variants and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000023590A2 (en) * 1998-10-20 2000-04-27 Georgetown University Medical Center INHIBITION OF CD40-MEDIATED NFλB ACTIVATION
WO2001096397A2 (en) * 2000-06-09 2001-12-20 Biogen, Inc. Cd154 variants and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
STUBER ECKHARD ET AL: "Blocking the CD40L-CD40 interaction in vivo specifically prevents the priming of T helper 1 cells through the inhibition of interleukin 12 secretion", BIOSIS, 1996, XP002189392 *

Also Published As

Publication number Publication date
EP1423144A2 (en) 2004-06-02
CA2467919A1 (en) 2003-02-20
AU2002313811A1 (en) 2003-02-24

Similar Documents

Publication Publication Date Title
DE60231601D1 (en) DEVICE AND METHOD FOR TREATMENT
EP1469871A4 (en) METHOD FOR TREATING APOPTOSIS AND COMPOSITIONS THEREFOR
EP1651164A4 (en) COMPOSITION AND METHOD FOR THE TREATMENT OF NEUROLOGICAL ILLNESSES
EP1482962A4 (en) METHOD FOR THE TREATMENT OF TRX-MEDIATED ILLNESSES
EP1701664A4 (en) SYSTEM AND METHOD FOR THE TREATMENT OF TISSUE
DE60227095D1 (en) COMPOSITIONS AND METHODS FOR TREATING SEPARATED GIPS
DE60239796D1 (en) PROCESS AND DEVICE FOR SAFE TRANSCODING
DE60138129D1 (en) APPARATUS FOR THE TREATMENT OF TEETH
EP1507765A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISORDERS OF THE CENTRAL AND PERIPHERAL NERVOUS SYSTEM AND NEW COMPOUNDS SUITABLE THEREFOR
DE60135049D1 (en) Method and device for improved chamber cleaning
DE60143831D1 (en) TAILORED ROHTEIL AND METHOD FOR THE PRODUCTION OF THE PART
DE60116035D1 (en) Process and apparatus for wastewater treatment
DE60235578D1 (en) TIRE TREATMENT METHOD
DE60227877D1 (en) Method and device for thermal treatment of substrates
DE60208186D1 (en) CHINAZOLIN AND CHINAZOLE-SEAL COMPOUNDS FOR THE TREATMENT OF INTEGRIN-MEDIATED ILLNESSES
DE50210076D1 (en) METHOD AND DEVICE FOR CONVERSION OF VIDEO SIGNALS
DE60233221D1 (en) METHOD FOR CLEANING HIGHER DIAMOND-STRUCTURAL COMPOUNDS AND THESE PREPARATIONS CONTAINING THEREOF
DE60142605D1 (en) Method and device for plasma treatment
DE60218451D1 (en) 15-KETO-PROSTAGLANDINE FOR THE TREATMENT OF DRUG-INDUCED OBSTIPATION
DE60122839D1 (en) Process for the treatment of chromate polluted wastewater
DE60223688D1 (en) METHOD FOR THE TREATMENT OF MULTIPLE MYELOMA
ATA17552001A (en) METHOD FOR TREATING ACID WASTE
DE60014876D1 (en) COMPOUNDS AND METHODS FOR TREATING ASTHMA, ALLERGY AND INFLAMMATORY DISEASES
EP1487480A4 (en) FUSION MOLECULES AND METHOD FOR THE TREATMENT OF IMMUNE DISEASES
DE50214806D1 (en) METHOD AND DEVICE FOR EXHAUSTION TREATMENT

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040309

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060705

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20060629BHEP

Ipc: G01N 33/50 20060101ALI20060629BHEP

Ipc: A61K 39/00 20060101ALI20060629BHEP

Ipc: A61K 38/00 20060101AFI20060629BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ROSKAMP RESEARCH LLC

17Q First examination report despatched

Effective date: 20080303

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100302